Tilray Accelerates Global Growth with Addition of Top Talent from European Beverage and Pharma Industries

Tilray (NASDAQ: TLRY) provided investors with an update this morning on their international cannabis operations. The company announced the expansion of its European leadership team with the addition of 5 key personnel from Europe’s beverage and pharmaceuticals space.

Appointed to Tilray‘s European team was Arne Wilkens as Vice President of European Business Expansion, José Tempero as European Medical Affairs Director, Maike Gerlach as Vice President of European Marketing, and Nadja Frenzel as Vice President of European Commercial Development. Tilray also added Natalie Bucceri to their team as Director of Global Portfolio Expansion.

“Having strong people on our team is critical to our success and growth,” says Sascha Mielcarek, Tilray’s Managing Director of Europe. “We’re thrilled to welcome this group of highly skilled leaders to our team. Arne, José, Maike, Nadja, and Natalie all join Tilray with wide-ranging experience in regulated industries. We’re confident their appointments will accelerate our global growth strategy and help strengthen our position in Europe and other international markets.”

Tilray expects its new leadership team additions to further accelerate the company’s European and global expansion strategy. Tilray’s EU Campus in Portugal will serve as the company’s primary hub for the cultivation, processing, research, and distribution of branded Tilray products into Europe and other international markets.

Source: Shutterstock

Let’s take a deeper look at Tilray’s 5 new additions:

Arne Wilkens, VP, Business Expansion, Europe:

14 years experience in pharma and biotech industries.
- Mostly in business development roles.
Most recent job was at AiCuris Anti-infective Cures GmbH.
- Served as Director of Business Development and Alliance Management.
  - Oversaw all partner activities, market analytics, commercial evaluations, and external partnerships.
Graduated with a master’s degree in management from Otto-von-Guericke University.

José Tempero, Medical Affairs Director, Europe:

11 years of pharmaceutical industry experience.
- Expert in medical affairs and market access.
Most recent job was at Grünenthal GmbH.
- Led their product-based global medical affairs strategy.
Holds a Master of Science in public health degree.
- Also professionally trained as a pharmacist.

Maike Gerlach, VP, Marketing, Europe:

17 years of pharmaceutical industry marketing experience.
Came to Tilray from Grünenthal GmbH.
- Was GmbH’s Associate Director of Integration Marketing.
  - Responsible for managing the global integration of Zomig®.
    - Zomig® was acquired from Astra Zeneca.
  - In her previous role, she successfully built and executed the brand’s global strategic marketing plan.

Nadja Frenzel, VP, Commercial Development, Europe:

Previously worked for Grünenthal GmbH.
- Worked on their Global Commercial Leadership team and contributed to the global commercial strategy.
  - Established a new, competitive, commercial model across the marketing, medical, market access, and commercial excellence departments.
Holds a Master of Science in health policy, economics, and management from Maastricht University in the Netherlands.

Natalie Bucceri, Director, Global Portfolio Expansion:

Recently worked for Diageo.
- Led projects to develop and implement short-term investment trade-offs and long-term strategic initiatives.
Before Diageo, she worked with the Merck & Co Asia Pacific executive team on core strategic and business-development projects.
Has professional experience in Europe, the United States, Asia, Australia, and New Zealand.
Will be based in the U.K. and work directly with the global expansion team.
- Her immediate focus will on the European market.

Tilray remains committed to being a leading supplier of pharmaceutical-grade medical cannabis products worldwide. To date, Tilray has successfully exported its products to many European countries including the Czech Republic, Germany, the United Kingdom, Cyprus, and Croatia. The company has also exported to the United States, Argentina, Chile, South Africa, Australia, and New Zealand. Tilray promises to continue releasing additional products in new markets as the company expands across the globe.

Investors looking for additional information on Tilray are encouraged to visit the company’s website here.

Additional investor due diligence links: Tilray IR Website & Tilray Investor Deck

Stay up to date with all things Tilray by following them on social media: Facebook, Twitter, and Instagram

About Tilray:

Tilray (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production, and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 12 countries spanning five continents.

Read the full Tilray press release